HARBOR CAPITAL ADVISORS, INC.
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1039128
CHICAGO, IL
Position in HALO
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$2,026,473
+$2,010,399 QoQ
Shares Held
31,355
+10047.2% QoQ
Ownership
0.026%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HARBOR CAPITAL ADVISORS, INC. holds $23,126,231 across 27 Biotechnology names. HALO ranks #5 (8.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KYMR |
Kymera Therapeutics, Inc.
|
33,948 | $2,827,528 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
30,353 | $2,639,800 | |
| 3 | TARS |
Tarsus Pharmaceuticals, Inc.
|
29,283 | $2,054,202 | |
| 4 | VCEL |
Vericel Corp
|
63,718 | $2,049,808 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
This page
|
31,355 | $2,026,473 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
83,196 | $1,742,956 | |
| 7 | SRPT |
Sarepta Therapeutics, Inc.
|
80,085 | $1,742,649 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
43,005 | $1,454,859 |
All Filings in HALO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,026,473 | 31,355 | Shares | Sole | 2026-04-28 | |
| 2025-06-30 | $16,074 | 309 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $21,440 | 336 | Shares | Sole | 2025-04-14 | |
| 2024-12-31 | $11,665 | 244 | Shares | Sole | 2025-01-10 | |
| 2024-09-30 | $13,222 | 231 | Shares | Sole | 2024-10-29 | |
| No filing history on record for this holder in this stock. | ||||||